{
  "docId": "019de077-4649-72e2-aa45-017392de211d",
  "docSlug": "8a7a8508ae9537047e1aabcda9819db4",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 27 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 27,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a bulleted list to present key clinical trial outcomes, including p-values and percentage improvements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4649-72e2-aa45-017392de211d/20",
  "deckHref": "/decks/019de077-4649-72e2-aa45-017392de211d",
  "deckJsonHref": "/decks/019de077-4649-72e2-aa45-017392de211d.json",
  "deckAnchorHref": "/decks/019de077-4649-72e2-aa45-017392de211d#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Results suggest a disease-modifying effect of PrimeC, positioning it as a potential first-line treatment for ALS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6e28839-4d91-4bef-a0c2-7019540749e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.77,
        "y": 0.7
      },
      "kind": "image",
      "text": "PARADIGM logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c049bf47-8dc0-4cb8-ae87-56c418815535",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Favorable safety and tolerability profile, achieving primary endpoint\nPrimeC improved disease progression (ALSFRS-R) by 29.2% after 6 months (p= 0.12), reaching statistical significance after 4 months of treatment (p=0.05)\nPrimeC treatment demonstrated 36.6% improvement in disease progression (ALSFRS-R) after 12 months compared to those who initially received placebo (p=0.009)\nPrimeC slowed functional decline across multiple ALSFRS-R domains with most pronounced effect on speaking and swallowing\nPrimeC demonstrated potential better survival after 12 months by 43% (p=0.41)\nConsistently positive trends throughout all clinical outcomes\nPrimeC modulated transferrin and ferritin levels showing target engagement",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa797d8c-5550-4d06-86f0-7d1f087d697a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Summary of PARADIGM Phase 2b Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0edebee-1b65-4782-9f81-5931527490d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "0f58d3ea-5e98-49f4-85cd-ddb0895a7abe",
      "evidence": "Favorable safety and tolerability profile, achieving primary endpoint",
      "confidence": 0.7
    },
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "579e3308-ae85-4d0d-bad1-442db7be4881",
      "evidence": "Results suggest a disease-modifying effect of PrimeC, positioning it as a potential first-line treatment for ALS",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "5eda8f32-b05b-4081-b142-37763a2894eb",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases the results of PrimeC's clinical trials, including improvements in motor performance, neuronal survival, and disease progression",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}